ANKHD1-EIF4EBP3

Across TCGA pan-cancer cohorts, ANKHD1-EIF4EBP3 Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated ANKHD1-EIF4EBP3 data layer compared with 21 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher ANKHD1-EIF4EBP3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ANKHD1-EIF4EBP3 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SCLC show a favorable association.

DLBC, TGCT, and PAAD are the cancer types where ANKHD1-EIF4EBP3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	DFS	Median	II,III,IV	0.065	0.829	<.001	27	view →
TGCT	OS	Median	All	0.069	0.968	<.001	12	view →
PAAD	OS	Median	All	0.112	0.640	.004	12	view →
KICH	DFS	Median	All	0.121	0.867	.023	10	view →
UCEC	DFS	Median	II,III,IV	0.855	0.429	.021	10	view →
COAD	OS	Median	III,IV	0.219	0.694	.021	10	view →
SKCM	OS	Median	III,IV	0.223	0.729	<.001	8	view →
PRAD	DFS	Median	All	0.143	0.777	<.001	6	view →
SCLC	DFS	Median	All	1.000	0.216	.037	3	view →
LUSC	DFS	Median	II,III,IV	0.139	0.663	.027	3	view →
CESC	DFS	Median	All	1.000	0.519	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

ANKHD1-EIF4EBP3–DLBC (DFS)

Open the DLBC breakdown →